Assay News and Research

RSS

Soluble ACE2 microbody blocks SARS-CoV-2 entry into lung cells

A new study by researchers at NYU Langone Medical Center and Weill Cornell Medical College and published on the preprint server bioRxiv* in September 2020 reports the potential of an angiotensin-converting enzyme 2 (ACE2)-antibody Fc complex in a new format that seems to offer more significant inhibition of SARS-CoV-2.

21 Sep 2020

COVAM assay may help select convalescent plasma units for treatment of acute COVID-19

A recent study published on the preprint server bioRxiv* seeks to establish the pattern of antibody reactivity in COVID-19 convalescent plasma (CCP), which is widely being used as a therapy for seriously ill COVID-19 patients.

21 Sep 2020

In vitro testing suggests effective novel drug combinations for SARS-CoV-2

A recent study published on the preprint server bioRxiv* in September 2020 shows the value of drug combinations to enhance the therapeutic and preventive efficacy of such repositioned drugs in standard antiviral therapy.

20 Sep 2020

Lopinavir-ritonavir does not suppress SARS-CoV-2 activity in vitro

Among them is the combination of lopinavir and ritonavir, which have been in use in an attempt to reduce the severity of the disease. However, a new South Korean study published on the preprint server bioRxiv in September 2020 shows that this combination is ineffective against the virus.

20 Sep 2020

Large mother-child paired study promises more answers on COVID-19 in pregnancy

A new paper published in the preprint server medRxiv* in August 2020 reports the design and preliminary findings of an ongoing study on pregnant mothers and their children born during the pandemic.

20 Sep 2020

UConn researchers validate clinical feasibility of CRISPR-based platform for COVID-19 testing

In March, researchers in the Department of Biomedical Engineering-- a shared department in the schools of Dental Medicine, Medicine, and Engineering--began to develop a new, low-cost, CRISPR-based diagnostic platform to detect infectious diseases, including HIV virus, the novel coronavirus (SARS-CoV-2).

19 Sep 2020

S-pseudotyped VLPs offer promising COVID-19 vaccine platform

A new study published on the preprint server bioRxiv* in September 2020 reports on a Moloney murine leukemia virus (MLV) platform that produces VLPs expressing the important spike antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

18 Sep 2020

Study invalidates Ebselen and other broad-spectrum SARS-CoV-2 Mpro inhibitors

Other novel compounds with Mpro inhibitory activity have also been claimed to have antiviral activity. These include ebselen, disulfiram, tideglusib, carmofur, shikonin, and PX-12. A new research paper discusses the role of these molecules as potential Mpro inhibitors in the prevention of SARS-CoV-2 infection.

18 Sep 2020

Could pineapples be a new weapon against COVID-19?

Results of a recent research endeavor from the United States indicate that bromelain or bromelain rich pineapple stem may be utilized as an antiviral agent against coronavirus disease (COVID-19), but also for potential future coronavirus outbreaks. This exciting paper is currently available on the bioRxiv preprint server.

17 Sep 2020

Testing settled solids in sewage for SARS-CoV-2 more sensitive approach than testing influent

Many studies on the containment of the ongoing COVID-19 pandemic have dealt with the possible role of wastewater in predicting and detecting future outbreaks and understanding the epidemiology of COVID-19 disease. A recent study published on the preprint server medRxiv* in September 2020 shows that solid waste in sewage is a better substrate for testing than influent.

17 Sep 2020

Optimal antibody combinations and Fc binding inhibit SARS-CoV-2 in vivo

A recent study by researchers at the University of North Carolina at Chapel Hill and The Rockefeller University and published on the preprint server bioRxiv in September 2020 shows that a combination of neutralizing antibodies with intact Fc effector function can effectively reduce the viral load and prevent infection.

17 Sep 2020

ERS Genomics and Applied StemCell sign agreement on commercialization of CRISPR gene editing tools

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, today announced it has signed an agreement with Applied StemCell, Inc., a leading provider of stem cell, animal model, antibody discovery services and reagents.

17 Sep 2020

Point-of-care biomarker assay predicts traumatic brain injury in minutes

Intracranial abnormalities on CT scan in patients with traumatic brain injury (TBI) can be predicted by glial fibrillary acidic protein (GFAP) levels in the blood.

16 Sep 2020

Pfizer's anti-viral 3CL protease inhibitor shows antiviral potential against SARS-CoV-2

Now, a new study by researchers from Pfizer, University of Arizona, Purdue University, The Scripps Research Institute, and UC San Diego School of Medicine and published on the preprint server bioRxiv in September 2020 reports that an enzyme inhibitor may act in synergism with the approved antiviral remdesivir to suppress viral replication in COVID-19.

16 Sep 2020

Can amodiaquine short circuit this pandemic?

A recent study by the US researchers highlights the value of the human organ chip technology as a more robust and physiologically relevant platform for rapid drug repurposing, and suggest that amodiaquine may be used to prevent the infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

15 Sep 2020

Aigenpulse launches data analysis suite to automate flow cytometry

Aigenpulse is launching its CytoML Experiment Suite specifically aimed at streamlining and automating cytometry analysis at scale.

15 Sep 2020

New antibody assay for COVID-19 promises sensitive mass-scale detection

A new paper by researchers at McMaster University and Hamilton Health Sciences, published on the preprint server medRxiv in September 2020, reports on the development of a serologic assay that is suitable for sensitive high-throughput antibody testing for COVID-19.

15 Sep 2020

3D printed nanoparticle biosensing platform detects SARS-CoV-2 antibodies within seconds

Pandemics caused by novel infectious agents like the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Zika, or Ebola virus seriously impact human health and lives while also overwhelming health care systems all over the world. Early detection and diagnosis allow isolation of the infected patients and contact tracing, which can mitigate the spread of the virus and save lives, especially when a significant number of the patients are asymptomatic.

14 Sep 2020

RUDN geneticist finds a bifidobacterial protein that can reduce inflammation in COVID-19

A geneticist from RUDN University studied the effect of Bifidobacterium (intestinal bacteria) on the inflammatory process and discovered that their surface protein is capable of stopping excessive or uncontrollable inflammation, like the one observed in COVID-19 patients.

14 Sep 2020

Circadian rhythm affects SARS-CoV-2 infection and host immune response

In an interesting bioRxiv preprint paper, French researchers show that the time day can affect infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as well as guide subsequent host immune response – implying that circadian rhythm may well be a novel target for managing viral progression.

14 Sep 2020

Assay News and Research

Soluble ACE2 microbody blocks SARS-CoV-2 entry into lung cells

COVAM assay may help select convalescent plasma units for treatment of acute COVID-19

In vitro testing suggests effective novel drug combinations for SARS-CoV-2

Lopinavir-ritonavir does not suppress SARS-CoV-2 activity in vitro

Large mother-child paired study promises more answers on COVID-19 in pregnancy

UConn researchers validate clinical feasibility of CRISPR-based platform for COVID-19 testing

S-pseudotyped VLPs offer promising COVID-19 vaccine platform

Study invalidates Ebselen and other broad-spectrum SARS-CoV-2 Mpro inhibitors

Could pineapples be a new weapon against COVID-19?

Testing settled solids in sewage for SARS-CoV-2 more sensitive approach than testing influent

Optimal antibody combinations and Fc binding inhibit SARS-CoV-2 in vivo

ERS Genomics and Applied StemCell sign agreement on commercialization of CRISPR gene editing tools

Point-of-care biomarker assay predicts traumatic brain injury in minutes

Pfizer's anti-viral 3CL protease inhibitor shows antiviral potential against SARS-CoV-2

Can amodiaquine short circuit this pandemic?

Aigenpulse launches data analysis suite to automate flow cytometry

New antibody assay for COVID-19 promises sensitive mass-scale detection

3D printed nanoparticle biosensing platform detects SARS-CoV-2 antibodies within seconds

RUDN geneticist finds a bifidobacterial protein that can reduce inflammation in COVID-19

Circadian rhythm affects SARS-CoV-2 infection and host immune response

Microplate-based assays in microbiology research eBook eBook

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology

Latest News